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MaThe aim of this study was to evaluate the value of microvascular obstruction (MO) and infarct size as a percentage of
left ventricular mass (IS%LV), as measured by contrast-enhanced cardiac magnetic resonance, in predicting major
cardiovascular adverse events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction reperfused
by primary percutaneous coronary intervention. Individual data from 1,025 patients were entered into the pooled
analysis. MO was associated with the occurrence of MACE, deﬁned as a composite of cardiac death, congestive
heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% conﬁdence interval: 2.21 to 6.34). IS%
LV $25% was not associated with MACE (adjusted hazard ratio: 0.90; 95% conﬁdence interval: 0.59 to 1.37).
The authors conclude that MO is an independent predictor of MACE and cardiac death, whereas IS%LV is not indepen-
dently associated with MACE. (J Am Coll Cardiol Img 2014;7:930–9) © 2014 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
CE-CMR = contrast-enhanced
cardiac magnetic resonance
IS = infarct size
LV = left ventricular
MACE = major adverse cardiac
events
MO = microvascular
obstruction
pPCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
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931or inadequate myocardial tissue reperfusion des-
pite successful reopening of the infarct-related
artery (3).
No-reﬂow is thought to be a consequence of
microvascular obstruction (MO), caused by nu-
merous components, including distal atherothrom-
botic embolization, ischemic injury, reperfusion
injury, and susceptibility of the coronary microcircu-
lation to injury (2). No-reﬂow can be assessedwith cine
coronary angiography, ST-segment resolution mea-
sured on electrocardiography, and noninvasive
imaging techniques such as myocardial contrast
echocardiography and contrast-enhanced cardiac
magnetic resonance (CE-CMR).SEE PAGE 953In patients with STEMI, the presence and
magnitude of MO are visualized by CE-CMR, with
accurate and reproducible measurements of left
ventricular ejection fraction (LVEF) and infarct size
(IS) (4). Compared with myocardial segments
without MO, segments with MO are more likely to
demonstrate wall thinning and are less likely
to demonstrate improvement of segmental wall
thickening during follow-up study (5). Moreover,
MO is an important predictor of global functional
recovery after STEMI (6). Several studies suggest
that MO is associated with worse prognosis (7–13).
However, previous studies in this regard have been
hampered by a limited number of patients, evaluated a
combined clinical endpoint, and were single-center
studies (7–13). Furthermore, although intuitively IS
measured within 2 weeks after STEMI is an important
independent determinant of outcome, there is con-
ﬂicting evidence to support its independent predictive
value for major adverse cardiac events (MACE)
(9,12,14).
We performed a meta-analysis of individual
patient data to evaluate the hypotheses that MO and
IS expressed as a percentage of left ventricular
(LV) mass (IS%LV) are independent predictors of
MACE and cardiac death in patients with STEMI
undergoing pPCI.METHODS
STUDY SELECTION. The MEDLINE database was
searched for citations of in-human studies published
in English from January 2004 to April 2012, using the
following terms: microcirculation(MESH), magnetic
resonance imaging, myocardial infarction, and
microvascular obstruction. A total of 134 publications
were identiﬁed. Related studies from the referencelists of retrieved papers, and the bib-
liographies of the coauthors, were included.
Observational studies in STEMI patients who
underwent pPCI within 12 h of symptom
onset, followed by CE-CMR within 14 days,
were eligible for inclusion. Studies in >60
patients were invited to participate. In the
case of experimental studies, data from only
the placebo groups were included in the
analysis.
DATA COLLECTION. Requested variables
consisting of baseline characteristics, vari-
ables used in the CADILLAC (Controlled
Abciximab and Device Investigation to
Lower Late Angioplasty Complications) risk score
(15), the Zwolle primary PCI index (16), and the
Thrombolysis in Myocardial Infarction (TIMI)
risk score (17); baseline CE-CMR variables; and
clinical outcomes (MACE) were mentioned before-
hand in a protocol, along with study rationale and
study design. The protocol was sent to participating
centers. Previous approval of the individual study
design by a local ethics committee was necessary for
participation. Datasets from participating centers
were merged by the coordinating center (Erasmus
Medical Center, Rotterdam, the Netherlands).
Queries were sent to the primary investigators in
cases in which further data and clariﬁcation were
needed.
DEFINITIONS/CE-CMR. STEMI was deﬁned on the
basis of the deﬁnitions used by the authors of the
primary publications (8–13,18,19). All clinical and
angiographic variables were study based. Angio-
graphic left main coronary artery lesions were cate-
gorized as left anterior descending artery lesions.
Imaging was performed in different centers on 1.5-T
scanners from different vendors (Online Table 1).
The scanning protocols, CE-CMR parameters, and
data analysis have been described in the included
studies (8–13,18,19). All investigators but one used a
steady-state, free-precession sequence for cine CMR
(Online Table 1). LV end-diastolic volume, LV end-
systolic volume, and LVEF were short-axis based,
as provided by the investigators. If LV end-diastolic
and end-systolic volume were not indexed, the
Mosteller equation was used to adjust these for
body surface area. Late gadolinium enhancement
was performed by the different centers by use of a
(phase-sensitive) inversion recovery gradient echo
sequence. MO, as visualized with late gadolinium
enhancement, was deﬁned as any region of hypo-
enhancement within the hyperenhanced area. IS was
determined on short-axis images. IS was expressed
FIGURE 1 Compute
A computerized liter
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932both in grams and as a percentage of the LV mass (IS%
LV). IS%LV was determined by manual or automated
tracing of the infarct border. In patients with MO,
regions of hypoenhancement were included in the IS.
In 2 studies, patients with prior infarction were
included (8,12). In patients with prior myocardial
infarction, only the region indicative of acute infarc-
tion (8), corresponding with edema in T2-weighted
imaging (12), was measured in delayed-enhancement
images.
ENDPOINTS. The primary endpoint was the preva-
lence of major adverse cardiovascular events
(MACE), deﬁned as a composite of cardiac death,
myocardial re-infarction, and new congestive heart
failure, at 2 years. The secondary endpoint was cardiac
mortality. Congestive heart failure was deﬁned as
any symptom of cardiac decompensation requiring
hospitalization. The individual study investigators
provided previously deﬁned and used events (Online
Table 1). If a patient experienced more than
one event, the ﬁrst event was chosen for the com-
bined clinical endpoint. Patients were considered
at risk from the time of admission for the treatment
of STEMI.
STATISTICAL ANALYSIS. Continuous data with
normal distribution are presented as mean  SD.
Non-normally distributed variables are reported as
median with corresponding interquartile range
(IQR). Categorical variables are represented by fre-
quencies and percentages. Patients were categorizedrized Search
ature search of citations was performed.according to the presence of MACE. Differences in
continuous variables between categories of patients
were studied by the unpaired Student t test or the
Mann-Whitney U test (in cases of non-normal dis-
tribution). Proportions were compared using the
chi-square test or the Fisher exact test, where
applicable. The incidences of the primary and sec-
ondary endpoints are reported as Kaplan-Meier es-
timates at a follow-up of 2 years. As small infarcts
and minor decreases in LVEF might not have an
impact on outcome, the relationship between these
variables on outcome was investigated by plotting
IS%LV and LVEF against event-free survival. A log-
rank test was used to evaluate differences in
freedom from study endpoints between categories
of patients. Univariate and multivariate Cox
regression analyses, stratiﬁed by study, were used
to determine the prognostic value of MO, IS%LV,
and LVEF with respect to the primary and second-
ary endpoints. Predictors of cardiac death and
MACE in published reports—namely, age (>65
years); sex (female); the presence of diabetes, hy-
pertension, anterior myocardial infarction (culprit
lesion in the left anterior descending artery), or
multivessel disease; TIMI ﬂow grade after PCI
(reference: TIMI ﬂow grade after PCI of 0 or 1); and
CMR-based LVEF (12,16,17)—were entered into the
univariate regression model, along with MO, IS%LV,
LV end-diastolic volume index, and LV end-systolic
volume index (9). Variables that resulted in a
p value of <0.10 in the univariate Cox model were
entered into the multivariate Cox proportional
hazards model, with respect to multicollinearity. LV
end-systolic volume index was not entered into the
multivariate model due to a collinear relation with
LVEF (Pearson correlation: –0.774). We applied the
method of backward selection; all variables with a
p value of <0.05 remained. The proportional haz-
ards assumption was validated graphically. In cases
of missing data (the requested variable data were
unavailable in >5.0% of the cohort), these variables
were not taken into account in the regression
analysis (e.g., time to reperfusion and Killip class).
We report unadjusted hazard ratios (HRs) and
adjusted hazard ratios (aHRs), 95% conﬁdence in-
tervals (CIs), and p values. We determined the c-
index (20) to report on the performance of the
models to discriminate between patients with and
without the study endpoints. The incremental value
of IS%LV, LVEF, and MO was compared with that
from a model with established clinical variables. c-
Index models were developed on the basis of
multivariate Cox models. We applied, for these
models, a backward variable-selection method; all
FIGURE 2 Study Flow Chart
AMI ¼ acute myocardial infarction; CE-CMR ¼ contrast-enhanced cardiac
magnetic resonance; ICD ¼ implantable cardioverter-deﬁbrillator; NSTEMI ¼
non–ST-segment elevation myocardial infarction; pPCI ¼ primary percuta-
neous coronary intervention.
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933variables with a p value of <0.05 remained. Two-
sided probability values with an a level of #0.05
were considered to be statistically signiﬁcant. Sta-
tistical analysis was performed using the statistical
packages IBM SPSS Statistics version 20.0.01 (IBM
SPSS Statistics, IBM Corporation, Armonk, New
York) and SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina). Kaplan-Meier curves were drawn
with GraphPad Prism version 4.00 (GraphPad Soft-
ware Inc., San Diego, California).
RESULTS
PATIENT CHARACTERISTICS. We identiﬁed 10
eligible observational and experimental studies.
The principal investigators of these studies were
invited to participate in this collaborative analysis.
Eight of 10 investigators provided individual
patient data (Figure 1). In this pooled analysis,
2 studies with 193 potentially eligible patients were
not included due to investigator unresponsiveness
(14,21).
The individual study characteristics are summa-
rized in Online Table 1. The inclusion procedure
is shown in Figure 2. Of 1,488 AMI patients, 150 pa-
tients (10.1%) were unable to have a CMR examina-
tion, and 313 patients were excluded due to other
reasons (Figure 2). Consequently, data from 1,025
STEMI patients who underwent reperfusion by pPCI
between April 9, 1999 and September 28, 2008 were
included in the patient pooled analysis. The mean age
at inclusion was 59.7  12.7 years, and 77.7% of the
cohort were men (n ¼ 796). The median time to
reperfusion was 3.3 h (IQR: 2.1 to 4.9 h). CE-CMR was
performed within a median of 4 days (IQR: 2 to 6
days) after the occurrence of STEMI. MO was present
in 56.3% of patients in the overall cohort. Of patients
with TIMI ﬂow grade after PCI of 3 (927 of 1,019
[91.0%]), MO was present in 54.9%. The mean LVEF
was 48.0  12.3%. Of the entire cohort, 14.7% had a
severely depressed (<35%) LVEF. The baseline char-
acteristics of patients with MACE and patients
without MACE are compared in Table 1. The median
duration of available follow-up was 12 months (IQR:
4 to 21 months).
PREDICTORS OF MACE. The composite endpoint
occurred in 130 patients within 2 years of follow-up.
In 9 patients, an event occurred between the index
event and the CE-CMR study. Cardiac death
occurred in 25 patients; myocardial re-infarction, in
47 patients; and congestive heart failure, in 58 pa-
tients. The Kaplan-Meier estimate of freedom from
MACE at 2 years was 76.5% in patients with MO
versus 93.0% in patients without MO (p < 0.001).For both LVEF and IS%LV, nonlinear relationships
were observed (Figures 3 and 4). Therefore, these 2
variables were categorized using tertiles, which
provides a large number of events per category
while respecting nonlinearity. For LVEF, the ﬁrst
tertile (cutoff: 42.7%, simpliﬁed to #40%, used in
the CADILLAC risk score [15]) was compared to the
reference group (LVEF >40%). For IS%LV, the last
tertile (cutoff: 24.7%, simpliﬁed to $25%) was
compared to the reference group (IS%LV <25%).
The Kaplan-Meier estimate of freedom from MACE
at 2 years was 74.3% in patients with IS%LV $25%
versus 87.4% in patients with IS%LV <25% (p <
0.001). Kaplan-Meier curves for MACE by MO and
IS%LV in the entire cohort, and grouped by MO and
TABLE 1 Patient Characteristics
Entire Cohort
(n ¼ 1,025)
MACE
(n ¼ 130)
No MACE
(n ¼ 895) p Value
Demographics
Age, yrs 59.7  12.7 61.8  13.3 59.4  12.6 0.04
Male 796 (77.7) 94 (72.3) 702 (78.4) 0.12
BMI, kg/m2* 27.0  3.8 27.2  4.1 27.0  3.7 0.60
CV risk factors
Hypertension 530/1,012 (52.4) 70/128 (54.7) 460/884 (52.0) 0.58
Hypercholesterolemia 380/1,010 (37.6) 57/128 (44.5) 323/882 (36.6) 0.08
Current or prior smoking 507/1,023 (49.6) 54/130 (41.5) 455/893 (51.0) 0.02
Family history of MI† 278/937 (29.7) 37/121 (30.6) 241/816 (29.5) 0.81
Diabetes 176/1,012 (17.4) 35/128 (27.3) 141/884 (16.0) <0.001
Prior MI‡ 47/948 (5.0) 12/123 (9.8) 35/825 (4.2) 0.009
Prior CABG§ 10/947 (1.1) 2/123 (1.6) 8/824 (1.0) 0.51
Angiographic variables
Time to reperfusion 3.3 (2.1–4.9) 3.5 (2.1–4.9) 3.2 (2.1–4.9) 0.57
Infarct-related artery
LAD 514/1,023 (50.2) 73/128 (57.0) 441/895 (49.3) 0.10
RCA 413/1,023 (40.4) 43/128 (33.6) 370/895 (41.3) 0.10
LCA 96/1,023 (9.4) 12/128 (9.4) 84/895 (9.4) 0.99
N-vessel disease
1 563/1,004 (56.1) 53/126 (42.1) 510/878 (58.1) <0.001
2 280/1,004 (27.9) 39/126 (31.0) 241/878 (27.4) 0.41
3 161/1,004 (16.0) 34/126 (27.0) 127/878 (14.5) <0.001
Multivessel disease 441/1,013 (43.5) 73/127 (57.5) 368/886 (41.5) <0.001
TIMI ﬂow grade after PCI
0 14/1,019 (1.4) 6/129 (4.7) 8/890 (0.9) <0.001
1 14/1,019 (1.4) 5/129 (3.9) 9/890 (1.0) 0.009
2 64/1,019 (6.3) 9/129 (7.0) 55/890 (6.2) 0.73
3 927/1,019 (91.0) 109/129 (84.5) 818/890 (91.9) 0.006
Enzymatic IS
Maximal CKk 2,161 (1,040–4,160) 2,729 (1,169–6,024) 2,109 (1,031–3,913) 0.04
CE-CMR variables
Time from MI to CE-CMR, days¶ 4 (2–6) 4 (2–6) 4 (2–6) 0.57
Presence of MO 577 (56.3) 109 (83.8) 468 (52.3) <0.001
IS, %LV# 18.5 (9.2–28.3) 24.9 (14.4–37.4) 18.0 (8.9–26.7) <0.001
IS, g 22.3 (10.8–37.4) 33.7 (15.3–54.1) 21.0 (10.2–34.7) <0.001
LVEF, % 48.0  12.3 41.4  13.3 48.9  11.9 <0.001
LVESV, ml 80.5  35.7 94.7  42.0 78.4  34.2 <0.001
LVESV index, ml/m2 41.3  17.2 48.4  19.6 40.3  16.6 <0.001
LVEDV, ml 150.5  42.4 156.3  45.3 149.6  41.9 0.09
LVEDV index, ml/m2 77.4  19.6 80.5  20.9 77.0  19.4 0.05
Values are mean  SD, n (%), n/N (%), or median (IQR). Data missing in the following number of cases: *124 (12.1%), †88 (8.6%), ‡77 (7.5%), §78 (7.6%), k278 (27.1%), and
¶446 (43.5%) (reperfusion within 12 h). #Data missing in >7.5% of the cohort.
BMI¼ body mass index; CABG¼ coronary artery bypass grafting; CE-CMR¼ contrast-enhanced cardiac magnetic resonance; CK ¼ creatine kinase; CV¼ cardiovascular; IQR¼
interquartile range; IS¼ infarct size; LAD¼ left anterior descending; LCA¼ left circumﬂex artery; %LV¼ percentage of LV mass; LVEDV¼ left ventricular end-diastolic volume;
LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; MI ¼ myocardial infarction; MO ¼ microvascular obstruction; PCI ¼ percutaneous
intervention; RCA ¼ right coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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934IS%LV, are depicted in Figures 5 to 7. The Kaplan-
Meier estimate of freedom from MACE was 71.3%
in patients with IS%LV $25% with MO versus
94.9% in patients with IS%LV <25% without MO
(p < 0.001).
Univariate Cox regression is summarized in
Table 2. MO (HR: 4.68; 95% CI: 2.86 to 7.66), IS%
LV $25% (HR: 2.04; 95% CI: 1.42 to 2.92), andLVEF #40% (HR: 3.45; 95% CI: 2.40 to 4.97) were
associated with MACE on univariate Cox regression
analysis. Sex (HR: 1.34; 95% CI: 0.89 to 2.00) and
anterior myocardial infarction (HR: 1.30; 95% CI: 0.90
to 1.87) were not associated with MACE on univariate
Cox regression analysis.
Multivariate Cox regression is summarized in
Table 3. MO (aHR: 3.74; 95% CI: 2.21 to 6.34) and
FIGURE 3 Relationship Between LV Ejection Fraction and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
LV ejection fraction category (>60%, 50% to #60%, 40
to #50%, 30% to #40%, or <30%). LV ¼ left ventricular.
FIGURE 5 Relationship Between MO and Event-Free Survival
Values are Kaplan-Meier estimates in patients with microvascular
obstruction (MO) versus patients without MO, indicating the time
to major adverse cardiovascular events (MACE), follow-up 2
years.
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935LVEF #40% (aHR: 2.30; 95% CI: 1.48 to 3.58) were
associated with MACE, whereas IS%LV $25% and
diabetes were not independently associated with
MACE (model I). After the application of the backward
variable-selection method, ﬁve variables (age, multi-
vessel disease, TIMI ﬂow grade after PCI, MO, and
LVEF #40%) remained signiﬁcant (model II). In a
separate analysis, IS%LV, unadjusted for MO and
LVEF, but adjusted for age, multivessel disease,
and TIMI ﬂow grade after PCI, was associated with the
occurrence of MACE (aHR: 1.82; 95% CI: 1.26 to 2.63)
(data not shown).FIGURE 4 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
IS%LV category (0 to #10%, 10% to #20%, 20% to #30%, 30
to #40%, or >40%). IS%LV ¼ infarct size expressed as a per-
centage of left ventricular mass.The addition of IS%LV $25% to a model with age,
multivessel disease, and TIMI ﬂow grade after PCI
(model a) resulted in an increase of the c-index
from 0.59 to 0.61 (model b) in the prediction of
MACE. The addition of LVEF #40% resulted in an
increase from 0.59 to 0.66 (model c), with a further
increase to 0.70 (model e) when MO was added
(Table 4).
PREDICTORS OF CARDIAC DEATH. The Kaplan-
Meier estimate of freedom from cardiac death at
2 years was 96.7% (MO vs. no MO: 99.8% vs. 94.6%;FIGURE 6 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates in patients with IS%LV $25%
versus <25%, indicating the time to MACE, follow-up 2 years.
Abbreviations as in Figures 4 and 5.
FIGURE 7 Relationship Between MO and IS%LV and Event-Free Survival
Values are Kaplan-Meier estimates in patients with IS%LV$25% versus <25%, grouped by
the presence or absence of MO, indicating the time to MACE, follow-up 2 years. Abbre-
viations as in Figures 4 and 5.
TABLE 3 Association of Patient Characteristics With MACE at
2 Years: Multivariate Cox Regression Analysis
aHR 95% CI p Value
Model I*
Age 1.54 1.04–2.27 0.03
Diabetes 1.25 0.80–1.94 0.33
Multivessel disease 1.56 1.07–2.28 0.02
TIMI ﬂow grade after PCI 2.11 1.04–4.27 0.04
Presence of MO 3.74 2.21–6.34 <0.001
IS%LV $25% 0.90 0.59–1.37 0.63
LVEF #40% 2.30 1.48–3.58 <0.001
LVEDV index 1.00 0.99–1.01 0.58
Model II†
Age 1.58 1.08–2.30 0.02
Multivessel disease 1.56 1.08–2.27 0.02
TIMI ﬂow grade after PCI 2.25 1.14–4.45 0.02
Presence of MO 3.72 2.22–6.25 <0.001
LVEF #40% 2.40 1.63–3.53 <0.001
*Before backward variable selection in 970 patients, 118 events. †Backward
variable selection in 984 patients, 118 events.
aHR ¼ adjusted hazard ratios; other abbreviations as in Tables 1 and 2.
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936p < 0.001). The Kaplan-Meier estimate of freedom
from cardiac death at 2 years was 95.2% in patients
with IS%LV $25% versus 97.3% in patients with IS%
LV <25% (p < 0.21) (data not shown).
Univariate Cox regression is summarized in
Table 5. MO (HR: 15.02; 95% CI: 2.01 to 112.24) and
LVEF #40% (HR: 2.26; 95% CI: 1.01 to 5.05) were
associated with cardiac death on univariate Cox
regression analysis. IS%LV $25% was not associated
with cardiac death in a univariate Cox model (HR:
1.77; 95% CI: 0.80 to 3.89).TABLE 2 Association of Patient Characteristics With MACE at
2 Years: Univariate Cox Regression Analysis
HR 95% CI p Value
Demographics
Age 1.60 1.11–2.31 0.01
Sex 1.34 0.89–2.00 0.16
CV risk factors
Diabetes 1.66 1.09–2.53 0.02
Hypertension 0.97 0.67–1.42 0.89
Anterior MI 1.30 0.90–1.87 0.16
Angiographic variables
Multivessel disease 1.65 1.13–2.40 0.009
TIMI ﬂow grade after PCI 3.31 1.70–6.43 <0.001
CE-CMR variables
Presence of MO 4.68 2.86–7.66 <0.001
IS%LV $25% 2.04 1.42–2.92 <0.001
LVEF #40% 3.45 2.40–4.97 <0.001
LVESV index 1.03 1.02–1.04 <0.001
LVEDV index 1.02 1.01–1.02 <0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major cardiovascular events;
other abbreviations as in Table 1.Independent predictors on multivariate Cox
regression and their respective aHRs for cardiac death
at 2 years are summarized in Table 6. MO was asso-
ciated with the occurrence of cardiac death (aHR:
13.22; 95% CI: 1.75 to 99.82) when adjusted for age
(aHR: 2.21; 95% CI: 0.96 to 5.06) and LVEF #40%
(aHR: 1.66; 95% CI: 0.74 to 3.75).
DISCUSSION
The main ﬁndings of this study were that: 1) MO was
present in >50% of patients with STEMI reperfused
by pPCI (even in patients with TIMI ﬂow grade post
pPCI of 3, MO was present in >50% of patients); 2)
MO, IS%LV, and LVEF were predictors for MACE, with
value added to clinical risk factors; 3) MO wasTABLE 4 Incremental Value (c-Statistic) of MO, IS%LV,
and LVEF #40% in the Prediction of MACE at 2 Years
c-Statistic
Model a: age þ multivessel disease þ TIMI ﬂow grade
after PCI
0.59
Model b: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ IS%LV $25%
0.61
Model c: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40%
0.66
Model d: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40% þ IS%LV <25%
0.66
Model e: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40% þ MO
0.70
Abbreviations as in Tables 1 and 2.
TABLE 5 Association of Patient Characteristics With Cardiac
Death at 2 Years: Univariate Cox Regression Analysis
HR 95% CI p Value
Demographics
Age 2.18 0.95–5.01 0.07
Sex 1.33 0.50–3.54 0.57
CV risk factors
Diabetes 2.25 0.96–5.25 0.06
Hypertension 1.05 0.44–2.49 0.91
Anterior MI 1.41 0.64–3.10 0.40
Angiographic variables
Multivessel disease 0.78 0.35–1.76 0.55
TIMI ﬂow grade after PCI 2.51 0.58–10.87 0.22
CE-CMR variables
Presence of MO 15.02 2.01–112.24 0.01
IS%LV $25% 1.77 0.80–3.89 0.16
LVEF #40% 2.26 1.01–5.05 0.05
LVESV index 1.01 0.99–1.04 0.22
LVEDV index 1.00 0.98–1.02 0.91
Abbreviations as in Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 9 , 2 0 1 4 van Kranenburg et al.
S E P T E M B E R 2 0 1 4 : 9 3 0 – 9 Prognostic Value of Microvascular Obstruction
937associated with cardiac death when adjusted for age
and LVEF; and 4) IS%LV, adjusted for MO and LVEF,
was not an independent predictor of MACE or cardiac
death.
Previous studies that evaluated the prognostic
value of MO, IS%LV, and LVEF in STEMI patients
were limited by the inclusion of relatively small
study sample sizes; evaluated composite clinical
endpoints with “soft” components, including revas-
cularization or angina; and were single-center
studies (7–13). In the present internationally repre-
sentative patient pooled analysis, we were able to
assess the impact of CE-CMR variables on more
clinically relevant events. With a sample size of 1,025
patients, the statistical power of the present pooled
analysis was increased compared with that of previ-
ous single-center studies, which led to more robust
predictions.
Our ﬁnding that the value of IS%LV, measured
within 14 days after STEMI, is secondary to those of
MO and LVEF is remarkable. It is important to realizeTABLE 6 Association of Age, MO, and LVEF #40% With
Cardiac Death at 2 Years: Multivariate Cox Regression Analysis
aHR 95% CI p Value
Age 2.21 0.96–5.06 0.06
Presence of MO 13.22 1.75–99.82 0.01
LVEF #40% 1.66 0.74–3.75 0.22
N ¼ 760 patients, 25 events.
Abbreviations as in Tables 1, 2, and 3.that IS%LV is correlated with LVEF; however, LVEF
is affected by additional factors, such as previous
cardiovascular conditions, which might explain the
importance of LVEF as a predictor of MACE in the
present study. However, the univariate association
of IS with MACE, its correlation with LVEF, and its
contribution to the model as shown by an improve-
ment in the c-index suggest that IS%LV is an
attractive option as an endpoint in studies investi-
gating new treatments. The measurement of LVEF is
inﬂuenced by the presence of stunned myocardium,
the relevance of which remains a topic of research,
because most CMR studies are performed 4 to 7 days
after STEMI, when stunning may be only partially
resolved.
The ﬁnding that MO was, in addition to IS%LV and
LVEF, an independent predictor of MACE is in
concordance with ﬁndings from previous single-
center studies. In the largest study to date, by de
Waha et al. (12), IS adjusted for TIMI risk score, MO,
and LVEF was not an independent predictor of
adverse outcomes. We draw the same conclusion in
the present study, in which IS%LV and LVEF were
analyzed as continuous variables.
The cause of the detrimental effect of MO remains
speculative. Baks et al. (5) demonstrated that the
presence of MO in dysfunctional myocardial seg-
ments was associated with signiﬁcantly greater thin-
ning of the myocardium compared with that in
segments without MO at follow-up. In contrast
to segments without MO, segments with MO demon-
strated no improvement in segmental wall thickening
in a follow-up study at 5 months. Nijveldt et al. (6)
found that a signiﬁcant proportion of patients with
MO developed a signiﬁcant increase in LV end-
diastolic volume, with no improvement in LVEF,
whereas patients without MO showed a signiﬁcant
improvement in LVEF, at 4 months of follow-up. Both
of those studies suggest an important relation be-
tween MO and LV remodeling that potentially might
result in heart failure used as a MACE, as in the pre-
sent study.
In addition to having predictive value for conges-
tive heart failure, MO seems to be an important pre-
dictor of cardiac death. Reasons for cardiac death in
patients with MO have been demonstrated by Ito
et al. (22). Patients with no-reﬂow more often
had malignant arrhythmias, cardiac tamponade, and
early congestive heart failure compared with
patients without no-reﬂow. An explanation of those
ﬁndings might have been the reduced end-diastolic
wall thickness in MO-positive segments, which
might result in an increase in wall stress in the
affected and adjacent segments (5).
van Kranenburg et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 9 , 2 0 1 4
Prognostic Value of Microvascular Obstruction S E P T E M B E R 2 0 1 4 : 9 3 0 – 9
938The ﬁndings from the present study demonstrate,
in a large cohort, the prognostic value of MO in pa-
tients who sustained a STEMI. MO was present in
>50% of the study population, even, importantly, in a
large subgroup of patients with angiographic TIMI
ﬂow grade after PCI of 3. These ﬁndings suggest that
pPCI is not optimal yet and that there is a need for
future novel treatment strategies. Of the current
variables, MO is still the best predictor and probably
indicates which patients should be investigated
further. Screening for arrhythmias and progressive
dilation, with follow-up echocardiography or CE-
CMR, could potentially identify a high risk for car-
diac death. The ﬁndings of this study are relevant in
CMR trial design for the evaluation of the effects of,
for example, thrombectomy devices, vasodilators,
coronary post-conditioning, cell therapy, and glyco-
protein IIb/IIIa inhibitors (23) in patients with STEMI.
It is advisable to use, in addition to the measurement
of LVEF and IS%LV, MO as surrogate endpoint in CMR
trials in STEMI patients as MO and IS%LV might be
variables that represent separate pathophysiological
processes.
STUDY LIMITATIONS. The results of our study should
be viewed in light of limitations inherent to the
design of meta-analyses of individual patient data.
These limitations include publication bias, data-
availability bias, unmeasured heterogeneity in the
patients included, and the use of event adjudication
by different clinical events committees (24).
CE-CMR was performed at a wide range of days
(up to 14) after STEMI, at different time points after
contrast injection, and with different concentrations
of gadolinium-based contrast agents (25). Thesevariations may have inﬂuenced the detection of MO
and may have inﬂuenced the measurement of IS (26).
CE-CMR analysis was conducted in different ways,
which also might have inﬂuenced the measurements
of IS and MO.
In this analysis, we evaluated the prognostic value
of MO only, without investigation of the extent of
MO. A previous study (12) showed that the extent of
MO provided incremental prognostic information.
Unfortunately, this variable was available in only one
study and therefore could not be included in the
pooled analysis.
In cases of missing data, variables that may have
inﬂuenced the primary endpoint (e.g., extent of MO,
myocardial salvage [27], and the presence of a hypo-
intense infarct core [28]) were not taken into account.
Due to a low cardiac death rate, we were not able to
add more variables in the multivariate Cox regression
analysis.
CONCLUSIONS
MO is an independent predictor of the occurrence
of MACE and cardiac death at 2 years in patients
with STEMI. IS%LV is not independently associated
with the occurrence of MACE, but might be
used, in addition to MO and LVEF, as a surrogate
endpoint in clinical trials investigating new treat-
ment options.
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